Autori: Cohen Jeffrey
| Naslov | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (Article) |
| Autori | Cohen Jeffrey ... Stojanovic Miroslav ... (broj koautora 18) |
| Info | LANCET, (2012), vol. 380 br. 9856, str. 1819-1828 |
| Projekat | Genzyme (Sanofi); Bayer Schering Pharma; Biogen Idec; Elan; Five Prime Therapeutics; Lilly; Novartis; Teva; Vaccinex; Waterfront Media; Genzyme; Merck Serono; Bayer; Coronado Biosciences; Consortium of Multiple Sclerosis Centers; Eli Lilly; EMD Serono; Ge |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
